Results 21 to 30 of about 357,928 (304)

Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials

Trials, 2022
Background Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the optimisation of recruitment strategies.
Thomas Williams, Sarah Alexander, James Blackstone, Floriana De Angelis, Nevin John, Anisha Doshi, Judy Beveridge, Marie Braisher, Emma Gray, Jeremy Chataway, on behalf of the MS-SMART and MS-STAT2 Investigators   +10 more
doaj   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta, Annecca, Rosanna, Aragri, Marianna, Ciardi, Maria R, Iannetta, Marco, Mastroianni, Claudio M, Pontecorvo, Simona, Russo, Gianluca, Salpini, Romina, Svicher, Valentina, Vullo, Vincenzo, Zingaropoli, Maria A   +11 more
core   +1 more source

Comparison of Neurite Orientation Dispersion and Density Imaging and Two-Compartment Spherical Mean Technique Parameter Maps in Multiple Sclerosis

Frontiers in Neurology, 2021
Background: Neurite orientation dispersion and density imaging (NODDI) and the spherical mean technique (SMT) are diffusion MRI methods providing metrics with sensitivity to similar characteristics of white matter microstructure.
Daniel Johnson, Daniel Johnson, Antonio Ricciardi, Antonio Ricciardi, Wallace Brownlee, Baris Kanber, Baris Kanber, Ferran Prados, Ferran Prados, Ferran Prados, Sara Collorone, Enrico Kaden, Enrico Kaden, Ahmed Toosy, Ahmed Toosy, Daniel C. Alexander, Claudia A. M. Gandini Wheeler-Kingshott, Claudia A. M. Gandini Wheeler-Kingshott, Claudia A. M. Gandini Wheeler-Kingshott, Olga Ciccarelli, Olga Ciccarelli, Francesco Grussu, Francesco Grussu   +22 more
doaj   +1 more source

Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone (ACTH)

Frontiers in Neurology, 2013
Relapses in multiple sclerosis (MS) are disruptive and frequently disabling for patients, and their treatment is often a challenge to clinicians. Despite progress in the understanding of the pathophysiology of MS and development of new treatments for ...
Amy ePerrin Ross, Aliza eBen-Zacharia, Colleen J Harris, Jennifer eSmrtka   +3 more
doaj   +1 more source

Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)—study protocol for a randomised controlled trial

Trials, 2021
Introduction Multiple sclerosis is a chronic inflammatory, degenerative disease of the central nervous system manifesting at first with relapses in about 85% of cases.
Anne Christin Rahn, Lisa Wenzel, Andrea Icks, Alexander Stahmann, Jutta Scheiderbauer, Kristina Grentzenberg, Markus Vomhof, Joseph Montalbo, Tim Friede, Christoph Heesen, Sascha Köpke   +10 more
doaj   +1 more source

Talking About Harm and Benefit Information-The Challenges in Healthcare Practice [PDF]

, 2015
Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families.
Joaquim, João José Morais, 1969-, Martins, Diana Mafalda Miranda, Matos, Cristiano   +2 more
core   +2 more sources

Correction to: Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)—study protocol for a randomised controlled trial

Trials, 2021
An amendment to this paper has been published and can be accessed via the original article.
Anne Christin Rahn, Lisa Wenzel, Andrea Icks, Alexander Stahmann, Jutta Scheiderbauer, Kristina Grentzenberg, Markus Vomhof, Joseph Montalbo, Tim Friede, Christoph Heesen, Sascha Köpke   +10 more
doaj   +1 more source

Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial

BMJ Open, 2021
Introduction Process evaluations accompanying complex interventions examine the implementation process of the underlying intervention, identify mechanisms of impact and assess contextual factors.
Christoph Heesen, Sascha Köpke, Lisa Wenzel, Jutta Scheiderbauer, Markus van de Loo, Anne Christin Rahn   +5 more
doaj   +1 more source

Increased circulating levels of vitamin D binding protein in MS patients [PDF]

, 2015
Vitamin D (vitD) low status is currently considered a main environmental factor in multiple sclerosis (MS) etiology and pathogenesis. VitD and its metabolites are highly hydrophobic and circulate mostly bound to the vitamin D binding protein (DBP) and ...
Cortese, Antonio, Francisci, Silvia, Gauzzi, Maria Cristina, Gessani, Sandra, Mechelli, Rosella, Millefiorini, Enrico, Purificato, Cristina, Rinaldi, Arturo Ottavio, Salvetti, Marco, Sanseverino, Isabella   +9 more
core   +2 more sources

A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. [PDF]

, 2020
Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs (DMDs) during pregnancy. However, this knowledge is limited.
A Haghikia, AL Nguyen, C Weber-Schoendorfer, D Moher, E Lu, E Lu, E Portaccio, G Comi, HV De Las, J Thone, JP Higgins, L Shamseer, MK Houtchens, N Ebrahimi, PK Coyle, R Alroughani, R Boskovic, S Herbstritt, S Pernia, S Thiel, SC MacDonald   +20 more
core   +1 more source